DAIICHI SANKYO CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,592 JPY | +1.23% |
|
-1.12% | +18.29% |
| Apr. 10 | Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark | MT |
| Apr. 08 | AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication | MT |
ETFs positioned on Daiichi Sankyo Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 25.16% | 15 M€ | +3.72% | ||
| 4.18% | 251 M€ | +13.08% | ||
| 3.32% | 174 M€ | -.--% | - | |
| 3.32% | 51 M€ | -.--% | - | |
| 3.24% | 15 M€ | +11.22% | ||
| 2.78% | 81 M€ | +12.65% | ||
| 2.69% | 57 M€ | +15.58% | ||
| 2.19% | 14 M€ | +15.15% | ||
| 2.13% | 73 M€ | +12.10% | ||
| 1.96% | 10,207 M€ | +11.65% | ||
| 1.95% | 5,115 M€ | +11.54% | ||
| 1.71% | 26 M€ | +17.53% | ||
| 1.68% | 16,729 M€ | +11.02% | - | |
| 1.64% | 31,732 M€ | +11.91% | - | |
| 1.63% | 1,198 M€ | +10.96% | - | |
| 1.42% | 66,066 M€ | +12.14% | - | |
| 1.42% | 144,586 M€ | +12.16% | ||
| 1.42% | 20,721 M€ | +10.99% | - | |
| 1.35% | 18 M€ | +16.15% | - | |
| 1.29% | 4 M€ | +10.64% | ||
| 1.08% | 60 M€ | +11.29% | ||
| 0.99% | 67,864 M€ | +11.89% | ||
| 0.69% | 4 M€ | -.--% | - | |
| 0.68% | 717 M€ | +5.04% | ||
| 0.44% | 26 M€ | +0.92% | - | |
| 0.30% | 10 M€ | -3.35% | - | |
| 0.30% | 36 M€ | +1.14% | - | |
| 0.25% | 7 M€ | -0.20% | - | |
| 0.23% | 276 M€ | +11.40% | - |
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
4,536
JPY
Average target price
5,620
JPY
Spread / Average Target
+23.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.29% | 55.09B | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 4568 Stock
- Funds and ETFs Daiichi Sankyo Co., Ltd.
